Patient description: The patient is a 34-year-old obese woman who comes to the clinic with weight concerns. She is 165 cm tall, and her weight is 113 kg (BMI: 41.5). In the past, she unsuccessfully used antiobesity agents and appetite suppressants. She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher. She is married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She rarely exercises and movement seems to be hard for her. She is not able to complete the four-square step test in less than 15 seconds. She does not smoke or use any drugs. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her lab results: FBS: 98 mg/dl TG: 150 mg/dl Cholesterol: 180 mg/dl LDL: 90 mg/dl HDL: 35 mg/dl She is considering a laparoscopic gastric bypass.

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  Type 2 Diabetes Ability to give informed consent and comply with all study requirements 2. Overweight and obese, generally healthy men and women. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history (with the exception of glucose tolerance, see below), full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests. 3. Glucose Parameters: 1. Fasting plasma glucose ≥100 mg/dL and <126 mg/dL 2. 2h post-OGTT glucose of ≥140 and <200 mg/dL 3. HbA1c<6.5% 4. Women of child-bearing potential are allowed (but must agree to use non-hormonal contraception and not plan to become pregnant for the duration of the study). Must agree to maintain the same contraceptive measures throughout the study. Acceptable contraceptive methods for female subjects of childbearing potential one of the following Abstinence One (1) of the following methods Tubal ligation Copper-containing intrauterine device (IUD) Condom AND spermicidal foam/gel/film/cream/suppository Male partner who has had a vasectomy for at least 6 months. 5. It is required that all male subjects use an acceptable method of contraception (as outlined below), starting from the first dose of study medication and continuing for at least 28 days after the last dose of study drug: 1. Abstinence 2. A condom AND one of the following Vasectomy for more than 6 months Female partner who meets one of the following conditions Has had a tubal ligation, hysterectomy, or bilateral oophorectomy; or  Subjects presenting with any of the following will not be included in the study: 1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, neoplastic, or allergic or clinical findings at Screening (seasonal allergies OK). 2. Any condition possibly affecting absorption (eg, gastrectomy, malabsorption syndromes, abdominal surgery other than appendectomy, cholecystectomy or hysterectomy). 3. Use of unacceptable medications 4. A positive urine drug screen. 5. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening. 6. Treatment with an investigational drug within 30 days or 5 half-lives preceding the first dose of study medication. 7. 12 lead ECG demonstrating QTc >450 msec at Screening for males, 470 msec for females. If QTc exceeds 450/470 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility. An ECG with evidence for possible old myocardial infarction will need to have prior ECGs to document stability of finding. 8. Supine blood pressure >=140 mm Hg (systolic) or 90 mm Hg (diastolic), on a single measurement. If elevated, confirm by a single repeat, following at least 10 minutes of rest. 9. Screening serum alanine transaminase (ALT) or serum aspartate transaminase (AST) greater than 2X the upper limit of the laboratory reference range. 10. Elevated fasting triglycerides at screening (>500 mg/dL), confirmed by a single repeat if deemed necessary. 11. Pregnant or nursing females; inability to use effective contraception. 12. Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing. 13. Participation in a clinical biomedical research study within prior two months may be excluded, depending on study type and details. 14. History of sensitivity to heparin or heparin-induced thrombocytopenia, if utilized by the site for blood draws. 15. Unwilling or unable to comply with directions and procedures described in this protocol. 16. Subject is the Investigator or a sub-Investigator, research assistant, pharmacist, study coordinator, other staff, or a relative of study personnel directly involved with the conduct of the study. 17. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study